Valproic acid
- Generic Name
- Valproic acid
- Brand Names
- Depakene, Depakote, Epival
- Drug Type
- Small Molecule
- Chemical Formula
- C8H16O2
- CAS Number
- 99-66-1
- Unique Ingredient Identifier
- 614OI1Z5WI
- Background
Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into the anticonvulsant effects o...
- Indication
Indicated for:
1) Use as monotherapy or adjunctive therapy in the management of complex partial seizures and simple or complex absence seizures.
2) Adjunctive therapy in the management of multiple seizure types that include absence seizures.
3) Prophylaxis of migraine headaches.
4) Acute management of mania associated with bipolar disorder.
...
- Associated Conditions
- Bipolar Disorder (BD), Complex Partial Seizure Disorder, Depressive Episodes, Migraine, Petit Mal Epilepsy, Seizure, multiple types, Acute Manic episode
- Associated Therapies
- -
Trial of Sodium Valproate in Amyotrophic Lateral Sclerosis
- Conditions
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2007-05-01
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 165
- Registration Number
- NCT00136110
- Locations
- 🇳🇱
UMC Utrecht, Utrecht, Netherlands
Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- First Posted Date
- 2005-05-04
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00109824
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors
- Conditions
- Interventions
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2014-08-07
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 26
- Registration Number
- NCT00107458
- Locations
- 🇨🇦
Hopital Sainte Justine, Montreal, Quebec, Canada
🇺🇸Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
🇺🇸Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study
- Conditions
- Interventions
- First Posted Date
- 2004-07-27
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 453
- Registration Number
- NCT00088452
- Locations
- 🇺🇸
Mattel Children's Hospital at UCLA, Los Angeles, California, United States
🇺🇸Children's Memorial Hospital, Chicago, Illinois, United States
🇺🇸Children's Hospital, Inc., PCTI, Columbus, Ohio, United States
Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT00084981
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Untreated Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Recurrent Adult Acute Myeloid LeukemiaRefractory Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 84
- Registration Number
- NCT00079378
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Valproic Acid in Treating Patients With Kaposi's Sarcoma
- Conditions
- First Posted Date
- 2004-01-13
- Last Posted Date
- 2014-08-29
- Lead Sponsor
- AIDS Malignancy Consortium
- Target Recruit Count
- 19
- Registration Number
- NCT00075777
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2003-12-31
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT00075010
- Locations
- 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States
Valproate in Dementia (VALID)
- First Posted Date
- 2003-10-31
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
- Target Recruit Count
- 313
- Registration Number
- NCT00071721
- Locations
- 🇺🇸
Lahey Clinic, Research Neurology, Burlington, Massachusetts, United States
🇺🇸Syracuse VA Medical Center, Syracuse, New York, United States
🇺🇸Medical University of South Carolina, North Charleston, South Carolina, United States
Valproate Response in Aggressive Autistic Adolescents
- Conditions
- First Posted Date
- 2003-08-05
- Last Posted Date
- 2005-06-24
- Target Recruit Count
- 30
- Registration Number
- NCT00065884
- Locations
- 🇺🇸
Outpatient MR/Autism Clinic, University of Kansas, Kansas City, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.